South Korea Loses Appeal Over $100 Million Payout to Elliott in Samsung Merger Dispute

South Korea faced a setback on Thursday when its appeal against a ruling requiring it to compensate U.S. hedge fund Elliott Management over $100 million was dismissed. The dispute stemmed from the contentious 2015 merger of two Samsung affiliates.
Last year, the Permanent Court of Arbitration (PCA) in the Netherlands ordered the South Korean government to pay Elliott Management approximately $108.5 million, encompassing damages, interest and legal fees. South Korea contested this decision at London’s High Court, arguing that the PCA lacked jurisdiction under the free trade agreement with the U.S. However, this appeal was rejected on Thursday, according to Reuters.
In response to the ruling, Elliott Management expressed satisfaction, stating that the decision was “the proper outcome based on well-established principles of English law.”
Related: Korea’s Antitrust Regulator Orders Samsung to Rectify Business Interference Practices
The hedge fund had taken legal action due to the involvement of South Korea’s National Pension Service in sanctioning an $8 billion merger between Samsung C&T and Cheil Industries, in which Elliott was a minority shareholder. This merger has also led to a separate lawsuit from New York hedge fund Mason Capital Management, which secured a judgment of about $32 million plus interest in April.
In addition to these civil cases, the merger has sparked criminal proceedings in South Korea. In February, Samsung Electronics Chairman Jay Y. Lee was acquitted of charges of accounting fraud and stock manipulation by a Seoul court. Prosecutors are currently appealing this verdict.
Source: Reuters
Featured News
Meta Begins Defense After FTC Concludes Case in Landmark Antitrust Trial
May 15, 2025 by
CPI
UK Data Bill Still No Closer to Passage As Parliamentary ‘Ping-Pong’ Drags On
May 15, 2025 by
CPI
Regeneron Pharmaceuticals Awarded $271.2M in Damages Against Amgen
May 15, 2025 by
CPI
FTC Chair Proposes 15% Staff Reduction Amid Budget Constraints
May 15, 2025 by
CPI
UK Urges Antitrust Watchdog to Prioritize Growth and Clarity in Business Regulation
May 15, 2025 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Healthcare Antitrust
May 14, 2025 by
CPI
Healthcare & Antitrust: What to Expect in the New Trump Administration
May 14, 2025 by
Nana Wilberforce, John W O'Toole & Sarah Pugh
Patent Gaming and Disparagement: Commission Fines Teva For Improperly Protecting Its Blockbuster Medicine
May 14, 2025 by
Blaž Višnar, Boris Andrejaš, Apostolos Baltzopoulos, Rieke Kaup, Laura Nistor & Gianluca Vassallo
Strategic Alliances in the Pharma Sector: An EU Competition Law Perspective
May 14, 2025 by
Christian Ritz & Benedikt Weiss
Monopsony Power in the Hospital Labor Market
May 14, 2025 by
Kevin E. Pflum & Christian Salas